Galectin Therapeutics updates corporate presentation; no new specific data in filing excerpt

GALECTIN THERAPEUTICS INC

Presentation dated September 2025 covers pipeline and strategy, but no clinical or financial figures are disclosed in the filing text.
Lead candidate belapectin (galectin-3 inhibitor) is highlighted without new trial results or milestones.
Forward-looking statements caution that actual results may differ materially from projections.
Investors should review the full presentation on the company's website for material updates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.